TickerFactsScreenerDevelopers

Denali Therapeutics Inc. (DNLI) — Operating Cash Flow

Annual figures by fiscal year, from SEC filings.

2016: -$71.91M2017: -$76.64M2018: $50.12M2019: -$151.58M2020: $416.15M2021: -$211.39M2022: -$244.72M2023: -$357.99M2024: -$347.69M2025: -$412.60M-$412.60M
2016Operating Cash Flow (USD)2025
Fiscal YearOperating Cash FlowChange YoY
2025-$412.60M-18.7%
2024-$347.69M+2.9%
2023-$357.99M-46.3%
2022-$244.72M-15.8%
2021-$211.39M-150.8%
2020$416.15M+374.6%
2019-$151.58M-402.5%
2018$50.12M+165.4%
2017-$76.64M-6.6%
2016-$71.91M—